Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + 5-fluorouracil + leucovorin calcium + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This regimen is a **combination therapy** consisting of four drugs: - **Bevacizumab**: a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis. - **5-fluorouracil**: an antimetabolite and pyrimidine analog that is incorporated into RNA and DNA, leading to inhibition of thymidylate synthase and cell death. - **Leucovorin calcium**: a reduced folate used to enhance the cytotoxic effect of 5-fluorouracil. - **Oxaliplatin**: a platinum-based chemotherapeutic agent that exerts its effect by forming DNA crosslinks. This combination, commonly referred to as **FOLFOX plus bevacizumab**, is widely used as a first-line chemotherapeutic regimen for metastatic colorectal cancer. The combination acts through multiple mechanisms: inhibition of tumor angiogenesis (bevacizumab), interference with DNA synthesis and repair (5-fluorouracil and oxaliplatin), and rescue/potentiation of 5-fluorouracil cytotoxicity (leucovorin)[1][2][3].
- Brand names
- Avastin
- Other names
- bevacizumab + 5-FU + leucovorin + oxaliplatinFOLFOX + bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + 5-fluorouracil + leucovorin calcium + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + 5-fluorouracil + leucovorin calcium + oxaliplatin.